CCSG supplement Year 2: Creating an efficient clinical trial build system via the Clinical Trials Rapid Activation Consortium (CTRAC)

项目概要/摘要 MD安德森癌症中心是德克萨斯大学内建立的综合性癌症中心 1941年制。2017年，该机构欢迎医学博士Peter Pisters担任其第五任全职总裁和PI。 CCSG。MD安德森的使命是通过以下方式消除德克萨斯州、全国和世界的癌症： 优秀的计划，整合病人护理，研究和预防，并通过教育， 本科生和研究生、受训人员、专业人员、雇员和公众。MD安德森是 致力于癌症研究，包括基础，临床和人口为基础的连续性 调查，重点是多学科的翻译研究。MD安德森雇用了超过 19，530人在FY 17，包括1，743名教职员工，其中705人（40%）是CCSG计划成员。 在2017财年，超过137，000人在MD安德森寻求护理，其中20，839人是新诊断的癌症 患者Web of Science的年度引用从2013年的3，260次增加到2017年的4，009次，增加了23%，其中包括 影响因子>10的期刊中有686篇（17%），影响因子>10的期刊中有244篇（6%） 20岁以上。总研究预算从2013年的6.71亿美元增加到2017年的8.44亿美元，增长了26%。直接成本NCI研究 赠款支持，不包括培训赠款和CCSG，增加了34%，从2013年的6700万美元增加到2018年的9000万美元， 在所有机构中获得NCI赠款最多（>200），包括6个SPORE，4个P01和35个U奖。 研究方案已减少到16个，并要求对14个共享资源提供支助。自上次 CCSG更新，研究得到加强，招聘了97名终身教职和终身教职教师， 其中18人获得了CPRIT总计6300万美元的招聘奖励。团队科学性得到增强 通过MD安德森的月球射击（3.83亿美元）的机构支持，重点是将死亡率从13 通过多学科的努力，建立在研究从CCSG计划出现的主要癌症。在 2017财年，10，283名参与者入组了1，108项干预性临床研究方案，其中936人 治疗（治疗）研究，共纳入6，271例受试者。在过去的十年里，MD安德森研究人员 作为一个新的实体， 新适应症，自上次CCSG更新以来获得了41项批准。除了主要医院外， 休斯顿地区提供前瞻性的多学科护理和支持服务， 强调获得临床试验，包括国家研究。癌症预防和生存是优先事项 为MD安德森，重点是分子流行病学，行为科学，临床癌症预防 和早期检测研究，以减少德克萨斯州和全世界的癌症负担。

PROJECT SUMMARY/ABSTRACT MD Anderson Cancer Center is a comprehensive cancer center established within the University of Texas System in 1941. In 2017, the institution welcomed Peter Pisters, MD, as its fifth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. MD Anderson employed more than 19,530 people in FY17, including 1,743 faculty members, of whom 705 (40%) are CCSG program members. More than 137,000 people sought care at MD Anderson in FY17 of whom 20,839 were newly diagnosed cancer patients. Annual citations in Web of Science have increased 23% from 3,260 in 2013, to 4,009 in 2017, including 686 (17%) articles in journals with an impact factor >10, and 244 (6%) articles in journals with an impact factor >20. The total research budget increased 26% from $671M in 2013 to $844M in 2017. Direct cost NCI research grant support, excluding training grants and the CCSG, has increased 34%, from $67M in 2013 to $90M in 2018, with the largest number of NCI grants for any institution (>200), including 6 SPOREs, 4 P01s and 35 U awards. Research Programs have been reduced to 16 and support is requested for 14 shared resources. Since the last CCSG renewal, research has been strengthened with recruitment of 97 tenured and tenure track faculty, of whom 18 are supported by recruitment awards from CPRIT totaling $63M. Team science has been enhanced through institutional support of the MD Anderson's Moon Shots ($383M), focused on reducing mortality from 13 major cancers through multi-disciplinary efforts that build on research emerging from the CCSG programs. In FY17, 10,283 participants were enrolled in 1,108 interventional clinical research protocols, of which 936 were treatment (therapeutic) studies that accrued 6,271 subjects. Over the past decade MD Anderson investigators have contributed to the clinical evaluation of 72 of 130 FDA oncology drug approvals, either as a new entity or for a new indication, with 41 of these approvals since the last CCSG renewal. In addition to the main hospital, Houston Area Locations provide prospective, multidisciplinary care and supportive services, with an increasing emphasis on access to clinical trials including national studies. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide.